143 related articles for article (PubMed ID: 9368086)
1. In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 and UR-9751, and comparison with fluconazole.
Stevens DA; Aristizabal BH
Diagn Microbiol Infect Dis; 1997 Oct; 29(2):103-6. PubMed ID: 9368086
[TBL] [Abstract][Full Text] [Related]
2. Efficacies of two novel azole derivatives each containing a morpholine ring, UR-9746 and UR-9751, against systemic murine coccidioidomycosis.
Clemons KV; Stevens DA
Antimicrob Agents Chemother; 1997 Jan; 41(1):200-3. PubMed ID: 8980782
[TBL] [Abstract][Full Text] [Related]
3. Treatment of murine cryptococcal meningitis with UR-9751 and UR-9746.
Restrepo MI; Najvar LK; Barchiesi F; Luther MF; Graybill JR
Med Mycol; 2000 Jun; 38(3):221-4. PubMed ID: 10892990
[TBL] [Abstract][Full Text] [Related]
4. Antifungal drug resistance in pathogenic fungi.
Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
[TBL] [Abstract][Full Text] [Related]
5. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.
Pfaller MA; Messer SA; Georgopapadakou N; Martell LA; Besterman JM; Diekema DJ
J Clin Microbiol; 2009 Dec; 47(12):3797-804. PubMed ID: 19794038
[TBL] [Abstract][Full Text] [Related]
6. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
7. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
8. In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.
Ramos G; Cuenca-Estrella M; Monzón A; Rodríguez-Tudela JL
J Antimicrob Chemother; 1999 Aug; 44(2):283-6. PubMed ID: 10473237
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.
Hata K; Kimura J; Miki H; Toyosawa T; Nakamura T; Katsu K
Antimicrob Agents Chemother; 1996 Oct; 40(10):2237-42. PubMed ID: 8891121
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antifungal activities of D0870, a new triazole agent.
Yamada H; Tsuda T; Watanabe T; Ohashi M; Murakami K; Mochizuki H
Antimicrob Agents Chemother; 1993 Nov; 37(11):2412-7. PubMed ID: 8285626
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
12. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Activities of Novel Azole Compounds ATTAF-1 and ATTAF-2 against Fluconazole-Susceptible and -Resistant Isolates of Candida Species.
Fakhim H; Emami S; Vaezi A; Hashemi SM; Faeli L; Diba K; Dannaoui E; Badali H
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795371
[TBL] [Abstract][Full Text] [Related]
14. Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus.
Wiederhold NP; Patterson HP; Tran BH; Yates CM; Schotzinger RJ; Garvey EP
J Antimicrob Chemother; 2018 Feb; 73(2):404-408. PubMed ID: 29190379
[TBL] [Abstract][Full Text] [Related]
15. Comparison of disk diffusion test and Etest for voriconazole and fluconazole susceptibility testing.
Buchta V; Vejsova M; Vale-Silva LA
Folia Microbiol (Praha); 2008; 53(2):153-60. PubMed ID: 18837162
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antifungal activities of FX0685, a novel triazole antifungal agent with potent activity against fluconazole-resistant Candida albicans.
Takahata S; Okutomi T; Ohtsuka K; Hoshiko S; Uchida K; Yamaguchi H
Med Mycol; 2005 May; 43(3):227-33. PubMed ID: 16010849
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
Pfaller MA; Messer SA; Hollis RJ; Jones RN
Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
[TBL] [Abstract][Full Text] [Related]
18. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo activities of CS-758 (R-120758), a new triazole antifungal agent.
Kamai Y; Harasaki T; Fukuoka T; Ohya S; Uchida K; Yamaguchi H; Kuwahara S
Antimicrob Agents Chemother; 2002 Feb; 46(2):367-70. PubMed ID: 11796343
[TBL] [Abstract][Full Text] [Related]
20. Current advances of triazole alcohols derived from fluconazole: Design, in vitro and in silico studies.
Emami S; Ghobadi E; Saednia S; Hashemi SM
Eur J Med Chem; 2019 May; 170():173-194. PubMed ID: 30897396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
